Biomatrix Alpha Drug Eluting Coronary stent

BioMatrix Alpha presents the best in class stent platform design with unique pro-healing coating from the pioneer in abluminal biodegradable technology.

It combines the proven safety of a DES with an abluminal biodegradable polymer, the proven efficacy of BA9™ and an innovative cobalt-chromium stent platform design.

Abluminal coating absorbed after 6 to 9 months
No drug carrier or drug inside the stent

•  Early BMS-like endothelial coverage
•  More targeted drug release
•  Reduced systemic exposure

BA9 Designed for Vascular Stent Technologies, optimized for local drug delivery

In the early 2000s the available mTOR inhibitor limus drugs, available for coronary stenting, were developed for systemic application. Biosensors developed its own proprietary limus technology by focusing during the early stages of drug development on its use for vascular technologies.

The Research and Development team developed several versions of Biolimus, through a number of iterations ultimately decided to focus on BA9 (Biolimus A9), as the best option for coronary stent application. Consequently, Biosensors' proprietary limus drug BA9  was used within its BioMatrix  DES family and BioFreedom DCS.
  

BA9 key characteristics

•  10 times more lipophilic than Sirolimus
•  Slower metabolism of drug due to its structure
•  High local bioavailability
•  Long 20-day half-life

Specifically designed pro-healing polymerNot all polymers are the same

•  Biosensors' PLA polymer degrades to naturally occuring Lactic Acid and Lactate
•  Lactate plays a key role in local arterial wound healing processes, mainly via enhanced Vascular Endothelial Growth Factor (VEGF) production

Alpha best-in-class performance vs. other stents